6 recruiting, 4 completed, 4 unknown, 2 active not recruiting. 18 Phase 2, 6 Phase 3, 4 Phase 1.
Follow Latent Infection: new trials by email Literature Review of Latent Infection trials Research Report on Latent Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV Rifapentine, Isoniazid, Dolutegravir - Tuberculosis | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 144 | 2026-09-28 | 2026-11-02 |
| BPaLMZ for TB Meningitis BPaLMZ Regimen - Tuberculous Meningitis, HIV | Phase 2 | Recruiting | David Boulware | 312 | 2026-07-28 | 2026-10-16 |
| Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB Bedaquiline, Isoniazid, rifapentine, Levofloxacin - Tuberculosis, Latent | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 2530 | 2026-05-08 | 2026-10-20 |
| Shorter and Safer Treatment Regimens for Latent TB rifampin standard arm, rifampin double dose, levofloxacin and rifapentine - Tuberculosis Infection, Latent | Phase 2 / Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 1800 | 2025-06-10 | 2026-05-11 |
| Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 252 | 2024-01-17 | 2025-12-12 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Control group, ASA group, IBU group - Tuberculosis, Pulmonary, Tuberculosis, MDR | Phase 2 | Terminated | Fundació Institut Germans Trias i Pujol | 426 | 2021-03-04 | 2026-06-01 |
| Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis Cyclophosphamide injection - Tuberculosis, Tubercular Meningitis | Phase 2 / Phase 3 | Unknown | All India Institute of Medical Sciences | 40 | 2021-01-01 | 2020-12-30 |
| ATG Individualized Dosing Model in URD-PBSCT. individualized ATG dosing strategy - Cytomegalovirus Infections, Infection Reactivation | Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2020-12-31 | 2024-12-03 |
| Tuberculosis Clinical Trials Consortium Study 35 Rifapentine, Isoniazid - Latent Tuberculosis | Phase 1 / Phase 2 | Completed | Centers for Disease Control and Prevention | 69 | 2019-11-12 | 2026-07-24 |
| 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB. Rifampin double dose, Rifampin triple dose, Rifampin standard dose - Latent Tuberculosis | Phase 2 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 1368 | 2019-09-20 | 2026-04-13 |
| Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks - Latent Tuberculosis | Phase 2 / Phase 3 | Recruiting | Centers for Disease Control and Prevention | 3400 | 2019-08-01 | 2026-05-06 |
| A Phase II Study of H56:IC31 in Healthy Adolescents H56:IC31, Placebo - Tuberculosis Infection | Phase 2 | Withdrawn | Aeras | 2018-06-01 | 2018-04-10 | |
| Efficacy of Nyaditum Resae(R) Against Active TB in Georgia Nyaditum resae(R), Placebo - Close Contacts of Active Tuberculosis | Phase 2 / Phase 3 | Unknown | Fundació Institut Germans Trias i Pujol | 3300 | 2017-03-10 | 2017-09-07 |
| A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456) H56ug/IC31nmol, Placebo - Latent Tuberculosis Bacteriology and Histology Unknown, Latent Tuberculosis | Phase 1 / Phase 2 | Completed | Aeras | 98 | 2013-08-01 | 2019-12-19 |
| Equivalence Study of Specificity of PPD Aplisol@ PPD material, Reference Standard - Tuberculosis Infection | Phase 2 | Unknown | JHP Pharmaceuticals LLC | 152 | 2013-02-01 | 2013-02-25 |
| Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard., Reactivity of Aplisol compared to reference standard PPD-S2. - Tuberculosis Infection | Phase 2 | Unknown | JHP Pharmaceuticals LLC | 168 | 2012-05-01 | 2012-09-21 |
| Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection RUTI, RUTI Matching Placebo - Latent Tuberculosis Infection, Tuberculosis | Phase 2 | Completed | Archivel Farma S.L. | 95 | 2010-06-01 | 2013-01-24 |
Latent Tuberculosis (17) · Tuberculosis (5) · Tuberculosis, Meningeal (2) · Tuberculosis, Pulmonary (2) · Arachnoiditis (1) · Communicable Diseases (1) · Cytomegalovirus Infections (1) · HIV Seropositivity (1) · Meningitis (1) · Tuberculosis, Multidrug-Resistant (1)
Infections (18) · Actinomycetales Infections (17) · Bacterial Infections (17) · Bacterial Infections and Mycoses (17) · Gram-Positive Bacterial Infections (17) · Mycobacterium Infections (17) · Tuberculosis (12) · Central Nervous System Bacterial Infections (2) · Central Nervous System Diseases (2) · Central Nervous System Infections (2) · Lung Diseases (2) · Meningitis, Bacterial (2) · Nervous System Diseases (2) · Neuroinflammatory Diseases (2)
rifapentine (6) · Isoniazid (5) · Rifampin (3) · Levofloxacin (2) · bedaquiline (2) · Aspirin (1) · Control Groups (1) · Cyclophosphamide (1) · Ethambutol (1) · Ibuprofen (1) · Moxifloxacin (1) · OPC-67683 (1) · Pyrazinamide (1) · Reference Standards (1) · Rifabutin (1)
Centers for Disease Control and Prevention (3) · Aeras (2) · Fundació Institut Germans Trias i Pujol (2) · JHP Pharmaceuticals LLC (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (2) · All India Institute of Medical Sciences (1) · Archivel Farma S.L. (1) · Chinese PLA General Hospital (1) · David Boulware (1) · Johns Hopkins University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · The Aurum Institute NPC (1)
South Africa (8) · Uganda (5) · Canada (4) · United States (4) · Vietnam (4) · Haiti (3) · Benin (2) · Georgia (2) · Indonesia (2) · Tanzania (2) · Australia (1) · Botswana (1) · Brazil (1) · China (1) · Kenya (1)
Dereck Tait, MD (2) · Dick Menzies, MD (2) · Amber Robinson, PhD (1) · Angelique Luabeya, MD (1) · Anneke Hesseling, MD (1) · Avy Violari, MD (1) · Cristina Vilaplana, MD, PhD (1) · Daniel W Fitzgerald, MD (1) · David Boulware, MD (1) · Dick Menzies (1) · Dr Vaneshree Govender (1) · Ekaterina V Kurbatova, MD, PhD, MPH (1) · Eric Nuermberger, MD (1) · Kelly Dooley, MD (1)
PMID 36730240, PMID 24586912, PMID 28043488, PMID 30092143, PMID 38552659, PMID 40915316, PMID 41504451, PMID 41624481